Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finlândia hair lotion in androgenetic alopecia
NCT04594018Phase 3Recruiting
- Sponsor
- EMS
- Start
- Feb 2023
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in androgenetic alopecia (AGA) (2 arms), sponsored by EMS. Primary endpoint: Change from baseline in hair density at 6 months. Started Feb 2023; status: recruiting.
02
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04594018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594018.